Short answer
Intellia Therapeutics, Inc. (NTLA) filed an 8-K current report with the SEC on September 8, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). FDA accepted Intellia’s biologics license application for lonvoguran ziclumeran in hereditary angioedema.
Intellia Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- FDA accepted Intellia’s biologics license application for lonvoguran ziclumeran in hereditary angioedema
- Priority review accelerates FDA evaluation and potential U.S. approval timeline
- Lonvo-z represents a potential commercial opportunity in HAE
- Press release details furnished as Exhibit 99.1
Item 8.01 · Other Events
- FDA accepted lonvo-z’s BLA for hereditary angioedema, advancing Intellia’s lead program into regulatory review
- Priority Review sets a March 10, 2027 PDUFA target action date, creating a defined approval catalyst
- FDA does not currently plan an advisory committee, potentially reducing an additional review hurdle
- Approval could make lonvo-z the first approved in vivo CRISPR therapy and only one-time HAE treatment
- Commercial launch preparations remain contingent on FDA approval and clinical, manufacturing, and intellectual-property risks
Item EX-99.1 · Exhibit EX-99.1
- FDA accepted lonvo-z’s BLA with Priority Review, setting a March 10, 2027 PDUFA action date
- Potential first approved in vivo CRISPR therapy and only one-time HAE treatment, creating significant commercial differentiation if approved
- Phase 3 HAELO showed 87% fewer monthly attacks versus placebo and 62% attack- and HAE-therapy-free patients versus 11%
- Trial enrolled 80 patients; one-time 50 milligram dosing produced no serious adverse events in the lonvo-z arm
- Regulatory milestone materially reduces review uncertainty, but approval and commercialization remain subject to FDA review and clinical risks
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Intellia Therapeutics, Inc. 8-K filings
Get the next NTLA 8-K as it lands
Follow NTLA for push alerts, or ask the research agent what this filing means.